Results 151 to 160 of about 43,144 (243)

Inflammatory Mediators Both Directly and Indirectly Promote Microglial Proliferation

open access: yesGlia, Volume 74, Issue 5, May 2026.
– CSF2, IL3, and TNFɑ directly promote microglial proliferation. – Neuron‐secreted factors suppress microglial proliferation. – IL1 cytokines promote CSF2 release from astrocytes, which promotes microglial proliferation. ABSTRACT Microglia—the predominant immune cell of the central nervous system (CNS)—possess an astounding capacity for proliferation ...
Brady P. Hammond   +4 more
wiley   +1 more source

Clinical Outcomes and Non‐Invasive Testing in Metabolic Dysfunction‐Associated Steatohepatitis With Cirrhosis: A Systematic Review

open access: yesLiver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) with cirrhosis lacks definitive treatments and poses an increasing healthcare burden globally. We undertook a systematic literature review (SLR) to better understand the disease burden in cirrhosis due to MASH.
Hannes Hagström   +8 more
wiley   +1 more source

GALNT10 Affects O‐Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer

open access: yesAdvanced Science, Volume 13, Issue 19, 2 April 2026.
The glycosyltransferase GALNT10 facilitates ovarian cancer metastasis through the induction of tumor cell EMT and tumor vascular dysfunction. GALNT10 enhanced the extracellular secretion of IGFBP7 through O‐GalNAc glycosylation modification at the T188 site, which subsequently interacts with CD93 on endothelial cells, leading to vascular remodeling ...
Yanan Zhang   +9 more
wiley   +1 more source

Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma [PDF]

open access: yes, 2013
Hepatocellular carcinoma (HCC) represents a global health problem. Infections with hepatitis B or C virus, non-alcoholic steatohepatitis disease, alcohol abuse, or dietary exposure to aflatoxin are the major risk factors to the development of this ...
Bacigalupo, Maria Lorena   +3 more
core   +1 more source

Therapeutic Galectin‐3 Apheresis Improves Sepsis Outcomes Through Coordinated Neutrophil Modulation and Endothelial Barrier Preservation: A Translational Study

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Gal‐3 apheresis reduces neutrophil hyperactivation (CXCL2/CXCL8, MPO, NETs), preserves endothelial barrier function (tight junctions, vWF/VCAM‐1/ICAM‐1), and attenuates PI3K/AKT/HIF‐1α signaling. These coordinated effects significantly improve hemodynamics, reduce pulmonary edema (ELWI), lower vasopressor and fluid requirements, and increase survival ...
Zhongyi Sun   +7 more
wiley   +1 more source

Galectin-1 (LGALS1) [PDF]

open access: yesScience-Business eXchange, 2011
openaire   +1 more source

Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Illustration of the microenvironment factors driving malignant progression in MPNSTs. ABSTRACT Neurofibromatosis type 1 (NF1) is characterized by the development of benign plexiform neurofibromas (PNFs). In 10%–15% of patients, these tumors undergo malignant transformation into aggressive malignant peripheral nerve sheath tumors (MPNSTs).
Ling‐Ling Ge   +11 more
wiley   +1 more source

Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 138, Issue 4, April 2026.
ABSTRACT Nintedanib, a multitargeted tyrosine kinase inhibitor, is approved for idiopathic pulmonary fibrosis (IPF) for its ability to slow lung function decline. This study systematically evaluated the effects of nintedanib across three independent treatment intervention studies in the single‐dose bleomycin (BLEO) mouse model of IPF.
Jamal Bousamaki   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy